U.S. markets closed

Intellia Therapeutics, Inc. (NTLA)

NasdaqGM - NasdaqGM Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
21.57+0.25 (+1.17%)
Al cierre: 04:00PM EDT
21.64 +0.07 (+0.32%)
Fuera de horario: 07:12PM EDT

Intellia Therapeutics, Inc.

40 Erie Street
Suite 130
Cambridge, MA 02139
United States
857 285 6200
https://www.intelliatx.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo526

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. John M. Leonard M.D.President, CEO & Director1.06MN/D1957
Mr. Glenn G. Goddard CPAExecutive VP, CFO & Treasurer630.91kN/D1971
Dr. Laura Sepp-Lorenzino Ph.D.Executive VP & Chief Scientific Officer670.58kN/D1961
Mr. James E. Basta Esq., J.D.Executive VP, General Counsel & Corporate Secretary616.15kN/D1966
Dr. David Lebwohl M.D.Executive VP & Chief Medical Officer671.42kN/D1955
Mr. Derek HicksExecutive VP & Chief Business Officer823.42kN/D1974
Mr. Nessan Bermingham Ph.D.Founder & Member of Scientific Advisor Board1.38MN/D1973
Dr. Rachel E. Haurwitz Ph.D.Co-FounderN/DN/D1986
Dr. Andrew May Ph.D.Founder and Member of Scientific Advisor BoardN/DN/DN/D
Dr. Jennifer A. Doudna Ph.D.Founder & Member of Scientific Advisor BoardN/DN/D1964
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Gestión corporativa

La calificación ISS Governance QuickScore de Intellia Therapeutics, Inc. a partir del 1 de abril de 2024 es 7. Las puntuaciones principales son Auditoría: 5; Junta: 8; Derechos del accionista: 8; Compensación: 5.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.